By clicking this link, you are agreeing to leave this Boehringer Ingelheim (Canada) Ltd. (BI) website and be directed to a non-BI website. BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.
This site is for Canadian healthcare professionals only.
Enter your license details to access the site
View coverage details for Trajenta® and Jentadueto®
Cookies are required to understand how you and other visitors use our websites
and applications and to improve your browsing experience. By using this website without changing
your browser settings, you consent to the use of cookies and other device identifiers. For more
information on our use of cookies, please review
the “Managing Cookies” section in our Privacy Policy.
Indications and clinical use
Monotherapy: Trajenta® is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance.
Add-on combination: Trajenta® is indicated for use in adult patients with type 2 diabetes mellitus to improve glycemic control in combination with: metformin, sulfonylurea (with or without metformin), metformin and empagliflozin, basal insulin (with or without metformin), when the therapy alone listed above, along with diet and exercise, does not provide adequate glycemic control.
No dosage adjustment is required based on age, however, greater sensitivity in some older individuals cannot be ruled out.
Safety and effectiveness has not been established in pediatric patients (<18 years of age), therefore Trajenta® should not be used in this patient population.
Contraindications
Patients with diabetic ketoacidosis or with type 1 diabetes mellitus
Relevant warnings and precautions
An association between DPP-4i treatment and heart failure was observed in cardiovascular outcomes trials for two other members of the DPP-4i class
Hypoglycemia: caution when used in combination with a sulfonylurea or insulin
Loss of glycemic control may occur in periods of stress
Use with strong inducers of P-gp or CYP3A4 (blood glucose monitoring recommended)
Not recommended in patients with severe hepatic impairment
Monitor for signs and symptoms of pancreatitis
Clinical trial/post-marketing reports of serious hypersensitivity reactions
Monitor blood glucose and HbA1c levels periodically
Assess hepatic function before starting treatment and periodically thereafter
Use with caution in patients with end-stage renal disease (ESRD) and those on dialysis
No studies on the effect on human fertility have been conducted
Ulcerative and necrotic skin lesions (monitoring for skin disorders is recommended)
Cases of bullous pemphigoid
Not recommended in pregnant and nursing women
For more information
Please refer to the Product Monograph at www.TrajentaPM.ca for important information relating to adverse events, drug interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.